Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution – Authors' reply

The Lancet Respiratory Medicine

Volumn 4, Issue 9, 2016, Pages e48-

  Kreuter, Michael ^a,b   Wuyts, Wim ^c   Renzoni, Elisabetta ^d   Koschel, Dirk ^e   Maher, Toby M ^d   Kolb, Martin ^f   Weycker, Derek ^g   Spagnolo, Paolo ^h   Kirchgaessler, Klaus Uwe ⁱ   Herth, Felix J F ^a,b   Costabel, Ulrich ^j  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b German Center for Lung Research (DZL)   (Germany)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e Fachkrankenhaus Coswig   (Germany)

^f MCMASTER UNIVERSITY   (Canada)

^g POLICY ANALYSIS INC PAI   (United States)

^h UNIVERSITY OF BASEL   (Switzerland)

ⁱ F HOFFMANN LA ROCHE LTD   (Switzerland)

^j RUHRLANDKLINIK   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; NINTEDANIB; PIRFENIDONE; PLACEBO; PROTON PUMP INHIBITOR;

CONSENSUS; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; FIBROSING ALVEOLITIS; HIGH RISK PATIENT; HUMAN; INFECTION RISK; LETTER; LUNG INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; TREATMENT RESPONSE;

EID: 84989894197     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(16)30235-1     Document Type: Letter

References (6)

1. 1 Kreuter, M, Wuyts, W, Renzoni, E, et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med 4 (2016), 381–389.
2. 2 Wuyts, WA, Bonella, F, Costabel, U, Cottin, V, Kreuter, M, Poletti, V, Spagnolo, P, An important step forward, but still a way to go. Am J Respir Crit Care Med 193 (2016), 340–341.
3. 3 Raghu, G, Rochwerg, B, Zhang, Y, et al. An official ATS/ERS/JRS/ALAT Clinical Practice Guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med 192 (2015), e3–19.
4. 4 Raghu G, Crestani B, Bailes Z, Schlenker-Herceg R, Costabel U. Effect of anti-acid medication on reduction in fvc decline with nintedanib. European Respiratory Society Annual Meeting; London, UK; Sept 3–7, 2015. Abstr OA4502.
5. 5 Ghebre, YT, Raghu, G, Idiopathic pulmonary fibrosis: novel concepts of proton pump inhibitors as antifibrotic drugs. Am J Respir Crit Care Med 193 (2016), 1345–1352.
6. 6 Abramowitz, J, Thakkar, P, Isa, A, Truong, A, Park, C, Rosenfeld, RM, Adverse event reporting for proton pump inhibitor therapy: an overview of systematic reviews. Otolaryngol Head Neck Surg, 2016, 10.1177/0194599816648298 published online May 17.